bullish

Key Iris II and Prima catalysts for H217

85 Views22 Aug 2017 16:08
Issuer-paid
SUMMARY

Pixium is building up a sales channel across Europe for its Iris II device, and is working on securing reimbursement and generating initial product sales in H217. It is also planning to start first-in-human trials for the next-generation Prima implant in H217. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €129.3m, compared to €131.4m, previously.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Edison Investment Research
Leading International Investment Research
Equities
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x